PRESS RELEASE published on 03/28/2025 at 14:37, 5 days 18 hours ago Annual financial and audit reports / Annual financial report
PRESS RELEASE published on 03/28/2025 at 14:32, 5 days 18 hours ago Rapports financiers et d'audit annuels / Rapport financier annuel
BRIEF published on 03/20/2025 at 07:05, 14 days 1 hour ago Innate Pharma annonce une conférence sur les résultats financiers 2024 Résultats Financiers Conférence Téléphonique Cotation Boursière Innate Pharma Immunothérapie Cancer
BRIEF published on 03/20/2025 at 07:05, 14 days 1 hour ago Innate Pharma Announces 2024 Financial Results Conference Financial Results Conference Call Stock Market Listing Cancer Immunotherapy Innate Pharma
PRESS RELEASE published on 03/20/2025 at 07:00, 14 days 1 hour ago Inside Information / Other news releases Innate Pharma to hold conference call and webcast for full year 2024 financial results on March 27, 2025. Details for participation provided Financial Results Conference Call Biotechnology Webcast Innate Pharma
PRESS RELEASE published on 03/20/2025 at 07:00, 14 days 1 hour ago Informations privilégiées / Autres communiqués Innate Pharma organise une conférence téléphonique et un webcast pour présenter ses résultats financiers 2024. Détails de l'événement et informations pratiques disponibles sur www.innate-pharma.com Résultats Financiers Webcast Conférence Téléphonique Innate Pharma Biotechnologies
BRIEF published on 02/17/2025 at 07:07, 1 month 14 days ago Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
BRIEF published on 02/17/2025 at 07:07, 1 month 14 days ago Innate Pharma Receives Breakthrough Therapy Designation from FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Sézary Syndrome
PRESS RELEASE published on 02/17/2025 at 07:02, 1 month 14 days ago Informations privilégiées / Autres communiqués Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA pour Lacutamab dans le syndrome de Sézary en rechute ou réfractaire. Accélération du développement réglementaire aux États-Unis FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
PRESS RELEASE published on 02/17/2025 at 07:02, 1 month 14 days ago Inside Information / Other news releases Innate Pharma receives U.S. FDA Breakthrough Therapy Designation for Lacutamab in Sézary syndrome treatment, showing promising results in Phase 2 TELLOMAK study FDA Innate Pharma Lacutamab Sézary Syndrome Breakthrough Therapy Designation
Published on 04/03/2025 at 05:10, 3 hours 36 minutes ago Battery X Metals Announces Corporate Awareness Agreement
Published on 04/03/2025 at 01:35, 7 hours 11 minutes ago GMV Minerals Inc. Closes Non-Brokered Financing/ Engages Investor Relations Firm
Published on 04/02/2025 at 23:35, 9 hours 11 minutes ago Murchison Minerals to Seek Shareholders’ Approval for Share Consolidation
Published on 04/02/2025 at 20:00, 12 hours 46 minutes ago Network-1 Announces Acquisition of Patent Portfolio
Published on 04/03/2025 at 08:30, 16 minutes ago ALVAREZ & MARSAL CREATES LEADING CORPORATE FINANCE PRACTICE IN SWITZERLAND BY JOINING FORCES WITH AVELA CAPITAL LED BY STEPHAN BRÜCHER
Published on 04/03/2025 at 08:15, 31 minutes ago 'CGTN: China-India ties at 75: 'Dragon-Elephant Tango' will benefit both'
Published on 04/03/2025 at 08:00, 45 minutes ago SWEF: Full Year Results for the Year Ended 31 December 2024
Published on 04/03/2025 at 08:00, 46 minutes ago Partnership with Claro: cyan AG advances into Latin American market and opens up new growth prospects
Published on 04/03/2025 at 08:00, 46 minutes ago Mise à disposition des documents préparatoires à l’Assemblée Générale Annuelle d’OPmobility SE
Published on 04/03/2025 at 08:00, 46 minutes ago Availability of preparatory documents for the Annual Shareholders’ Meeting of OPmobility SE
Published on 04/03/2025 at 00:37, 8 hours 8 minutes ago Publication of the report on payments made to governments provided by article L.225-102-3 of the French Commercial Code
Published on 04/03/2025 at 00:37, 8 hours 8 minutes ago Mise à disposition du rapport sur les paiements faits aux gouvernements prévu à l’article L.225-102-3 du Code de commerce
